CN103649106B - 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合 - Google Patents
用于治疗神经退行性和缺血性脑疾病的化合物和药学组合 Download PDFInfo
- Publication number
- CN103649106B CN103649106B CN201280032375.5A CN201280032375A CN103649106B CN 103649106 B CN103649106 B CN 103649106B CN 201280032375 A CN201280032375 A CN 201280032375A CN 103649106 B CN103649106 B CN 103649106B
- Authority
- CN
- China
- Prior art keywords
- pcb
- ifn
- seq
- peptide
- epo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011/0146 | 2011-07-01 | ||
| CU2011000146A CU23963B1 (es) | 2011-07-01 | 2011-07-01 | Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas |
| PCT/CU2012/000003 WO2013004203A1 (es) | 2011-07-01 | 2012-06-29 | Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103649106A CN103649106A (zh) | 2014-03-19 |
| CN103649106B true CN103649106B (zh) | 2016-01-20 |
Family
ID=46614264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280032375.5A Expired - Fee Related CN103649106B (zh) | 2011-07-01 | 2012-06-29 | 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9518085B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2733149B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6023803B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101987978B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103649106B (cg-RX-API-DMAC7.html) |
| AR (1) | AR087034A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012280776B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013033970B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2838496C (cg-RX-API-DMAC7.html) |
| CU (1) | CU23963B1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2733149T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2601887T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014CN00510A (cg-RX-API-DMAC7.html) |
| MX (1) | MX345534B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2569302C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2733149T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013004203A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201309554B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3013355B1 (en) * | 2013-06-25 | 2019-08-07 | ICM - Institut du Cerveau et da la Moelle Epinière | Il-2 for use in treating alzheimer disease and related disorders |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| RU2613765C1 (ru) * | 2016-01-26 | 2017-03-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" | Способ лечения спиноцеребеллярной атаксии |
| CN108752445B (zh) * | 2018-06-20 | 2021-04-30 | 广东药科大学 | 一种螺旋藻蛋白的制备工艺及其神经保护用途 |
| KR102152407B1 (ko) * | 2019-02-26 | 2020-09-07 | (주)나우코스 | 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물 |
| KR20210091664A (ko) | 2020-01-14 | 2021-07-22 | 경북대학교 산학협력단 | 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5709855A (en) | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| US7025965B1 (en) * | 2003-02-12 | 2006-04-11 | Pharma Chemie, Inc. | Method of use and dosage composition of bluegreen algae extract for inflammation in animals |
| US7534423B2 (en) * | 2003-03-28 | 2009-05-19 | Faron Pharmaceuticals Oy | Method for inducing an elevated level of adenosine in an individual |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| DK2046354T3 (da) * | 2006-06-27 | 2011-10-31 | Nutratec S R L | Aphanizomenon Flos Aquae-fremstilling, ekstrakter og oprensede bestanddele deraf til behandling af neurologiske, neurodegenerative og humørforstyrrelser |
| US8709434B2 (en) * | 2006-11-13 | 2014-04-29 | Pcb Associates, Inc. | Compositions for inhibiting NADPH oxidase activity |
-
2011
- 2011-07-01 CU CU2011000146A patent/CU23963B1/es unknown
-
2012
- 2012-06-29 AU AU2012280776A patent/AU2012280776B2/en not_active Ceased
- 2012-06-29 US US14/127,369 patent/US9518085B2/en active Active
- 2012-06-29 JP JP2014517444A patent/JP6023803B2/ja not_active Expired - Fee Related
- 2012-06-29 DK DK12743356.3T patent/DK2733149T3/en active
- 2012-06-29 RU RU2014103246/04A patent/RU2569302C2/ru active
- 2012-06-29 MX MX2013015206A patent/MX345534B/es active IP Right Grant
- 2012-06-29 IN IN510CHN2014 patent/IN2014CN00510A/en unknown
- 2012-06-29 WO PCT/CU2012/000003 patent/WO2013004203A1/es not_active Ceased
- 2012-06-29 CN CN201280032375.5A patent/CN103649106B/zh not_active Expired - Fee Related
- 2012-06-29 SI SI201230756A patent/SI2733149T1/sl unknown
- 2012-06-29 BR BR112013033970-5A patent/BR112013033970B1/pt not_active IP Right Cessation
- 2012-06-29 CA CA2838496A patent/CA2838496C/en active Active
- 2012-06-29 KR KR1020147002552A patent/KR101987978B1/ko not_active Expired - Fee Related
- 2012-06-29 ES ES12743356.3T patent/ES2601887T3/es active Active
- 2012-06-29 EP EP12743356.3A patent/EP2733149B9/en active Active
- 2012-07-02 AR ARP120102397A patent/AR087034A1/es unknown
-
2013
- 2013-12-18 ZA ZA2013/09554A patent/ZA201309554B/en unknown
-
2016
- 2016-11-10 US US15/348,451 patent/US20170119733A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| Bilin Attachment Sites in the a! and /3 Subunits of B-Phycoerythrin;Daniel J. Lundell;《THE JOURNAL OF BIOLOGICAL CHEMIST》;19841231;第259卷(第9期);pp. 5472-5480 * |
| Chromopeptides from C-phycocyanin. Structure and linkage of a phycocyanobilin bound to the .beta. subunit;J. Clark Lagarias , Alexander N. Glazer , Henry Rapoport;《J. Am. Chem. Soc》;19791231;第101卷(第17期);pp 5030–5037 * |
| In Vitro Attachment of Bilins to Apophycocyanin. 111. PROPERTIES OF THE PHYCOERYTHROBILIN ADDUCT;David M. Arciero;《J Biol Chem.》;19881205;第263卷(第34期);18358-18363 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014520764A (ja) | 2014-08-25 |
| CU20110146A7 (es) | 2013-02-26 |
| BR112013033970A2 (pt) | 2017-02-14 |
| CA2838496C (en) | 2020-01-07 |
| CN103649106A (zh) | 2014-03-19 |
| DK2733149T3 (en) | 2016-11-28 |
| RU2569302C2 (ru) | 2015-11-20 |
| EP2733149B9 (en) | 2019-05-15 |
| ES2601887T3 (es) | 2017-02-16 |
| BR112013033970B1 (pt) | 2022-10-18 |
| CU23963B1 (es) | 2013-12-11 |
| US9518085B2 (en) | 2016-12-13 |
| MX345534B (es) | 2017-02-03 |
| RU2014103246A (ru) | 2015-08-10 |
| US20140356319A1 (en) | 2014-12-04 |
| IN2014CN00510A (cg-RX-API-DMAC7.html) | 2015-04-03 |
| US20170119733A1 (en) | 2017-05-04 |
| AR087034A1 (es) | 2014-02-05 |
| EP2733149A1 (en) | 2014-05-21 |
| SI2733149T1 (sl) | 2017-01-31 |
| ZA201309554B (en) | 2014-08-27 |
| AU2012280776A1 (en) | 2014-01-23 |
| WO2013004203A1 (es) | 2013-01-10 |
| AU2012280776B2 (en) | 2016-07-14 |
| MX2013015206A (es) | 2014-02-20 |
| EP2733149B1 (en) | 2016-09-28 |
| JP6023803B2 (ja) | 2016-11-09 |
| KR101987978B1 (ko) | 2019-06-11 |
| KR20140078601A (ko) | 2014-06-25 |
| CA2838496A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170119733A1 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
| Collino et al. | Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin | |
| US9352024B2 (en) | Uses of interleukin-22(IL-22) in treating and preventing nerve damage diseases or neurodegenerative diseases | |
| EP3065765B1 (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
| AU2010203446B2 (en) | Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22 | |
| US20170002043A1 (en) | Novel peptides and methods and uses thereof for preventing retinal disorders | |
| NZ588437A (en) | Apoaequorin-containing compositions and methods of using same | |
| CN102205114B (zh) | 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用 | |
| DE112018001364T5 (de) | Verwendung von Lambda-Interferonen bei der Behandlung von mit Adipositas zusammenhängenden Störungen und verwandten Erkrankungen | |
| WO2001066133A1 (fr) | Agents d'amelioration de la resistance a la leptine | |
| CN117062617A (zh) | 脑损伤的组合治疗 | |
| KR20080098488A (ko) | Hiv 치료 | |
| ES2324306T3 (es) | Uso de il-17f para el tratamiento y/o la prevencion de enfermedades neurologicas. | |
| JPH10273448A (ja) | アトピー性疾患治療のための口腔内投与用治療薬 | |
| RU2461566C1 (ru) | Способ лечения злокачественных опухолей у млекопитающих | |
| JPH0827026A (ja) | 肝疾患の予防・治療薬 | |
| HK1223556B (en) | Use of il-22 dimers in manufacture of medicaments for treating pancreatitis | |
| WO2000024414A1 (fr) | Agents preventifs/curatifs pour les maladies du foie | |
| HK1109576B (en) | Aequorin-containing compositions and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 |